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ABSTRACT
Approximately 15% of pediatric B cell precursor acute lymphoblastic leukemia 
(BCP-ALL) is characterized by gene expression similar to that of BCR-ABL1-positive 
disease and unfavorable prognosis. This BCR-ABL1-like subtype shows a high 
frequency of B-cell development gene aberrations and tyrosine kinase-activating 
lesions. To evaluate the clinical significance of tyrosine kinase gene fusions in children 
with BCP-ALL, we studied the frequency of recently identified tyrosine kinase fusions, 
associated genetic features, and prognosis in a representative Dutch/German cohort. 
We identified 14 tyrosine kinase fusions among 77 BCR-ABL1-like cases (18%) and 
none among 76 non-BCR-ABL1-like B-other cases. Novel exon fusions were identified 
for RCSD1-ABL2 and TERF2-JAK2. JAK2 mutation was mutually exclusive with tyrosine 
kinase fusions and only occurred in cases with high CRLF2 expression. The non/late 
response rate and levels of minimal residual disease in the fusion-positive BCR-ABL1-
like group were higher than in the non-BCR-ABL1-like B-others (p<0.01), and also 
higher, albeit not statistically significant, compared with the fusion-negative BCR-
ABL1-like group. The 8-year cumulative incidence of relapse in the fusion-positive 
BCR-ABL1-like group (35%) was comparable with that in the fusion-negative BCR-
ABL1-like group (35%), and worse than in the non-BCR-ABL1-like B-other group 
(17%, p=0.07). IKZF1 deletions, predominantly other than the dominant-negative 
isoform and full deletion, co-occurred with tyrosine kinase fusions. This study shows 
that tyrosine kinase fusion-positive cases are a high-risk subtype of BCP-ALL, which 
warrants further studies with specific kinase inhibitors to improve outcome.
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INTRODUCTION
Children with B-cell precursor acute lymphoblastic 
leukemia (BCP-ALL) with the BCR-ABL1 fusion gene 
form a small patient group with a poor prognosis, which 
has been substantially improved in recent treatment 
protocols with the addition of imatinib and other tyrosine 
kinase inhibitors [1–2]. Approximately 15% of cases 
of BCP-ALL are characterized by a gene expression 
signature similar to that of BCR-ABL1-positive disease 
and an unfavorable prognosis [3–4]. This BCR-ABL1-
like subtype is found in approximately 50% of so-called 
B-other cases, which are BCP-ALL cases negative for 
the sentinel cytogenetic lesions BCR-ABL1, ETV6-
RUNX1, TCF3-PBX1, rearrangement of MLL, or high 
hyperdiploidy (51-65 chromosomes). BCR-ABL1-like 
BCP-ALL shows a high frequency of B-cell development 
gene aberrations, especially IKZF1 deletions [3–5], and 
tyrosine kinase activating lesions [6–7].
Tyrosine kinase activating lesions are diverse 
and include tyrosine kinase fusion proteins, cytokine 
receptor overexpression, or activating point mutations in 
genes encoding kinases, cytokine receptors, or signaling 
molecules (recently reviewed in [8]). In our study, we 
focus on tyrosine kinase fusion genes because they are 
most similar to the well-known BCR-ABL1 fusion gene 
and expected to be clonal leukemia drivers. Detection of 
tyrosine kinase fusions could guide targeted treatment 
with tyrosine kinase inhibitors and improve outcome 
in a similar way as currently for BCR-ABL1-positive 
patients.
Tyrosine kinases known to be involved in fusions 
include the ABL class kinases ABL1, ABL2, PDGFRB 
and CSF1R as well as the JAK class kinase JAK2. Each 
of these kinases has been detected in in-frame fusions 
with multiple 5’ partner genes resulting in the expression 
of a constitutively active, oncogenic kinase. The number 
of patients without sentinel chromosomal abnormalities 
and the diversity of novel tyrosine kinase fusions poses a 
challenge to routine fusion gene detection. Previous studies 
have described the discovery and oncogenic potential of 
ABL and JAK class fusion genes and the sensitivity of 
patients’ cells or in vitro cell models to tyrosine kinase 
inhibition [6–7]. Selection of patients for fusion detection 
in these studies was based on gene expression profiling 
indicating Philadelphia-like ALL [6–7]. A large Japanese 
study screened all B-other cases by transcriptome analysis 
or multiplexed RT-PCR for 15 fusions and found both 
methods similarly sensitive [9]. Other studies describe 
systematic screens in B-other cases by FISH or RT-PCR to 
detect specific tyrosine kinase fusions [10–11].
We aimed at the detection of recently identified 
tyrosine kinase fusion genes in 153 B-other cases of a 
population-based cohort of 574 Dutch/German pediatric 
BCP-ALL patients at initial diagnosis to address the 
frequency of tyrosine kinase fusions, their clinical 
response characteristics, and associated genetic lesions in 
B-cell development genes.
RESULTS
Tyrosine kinase fusions are restricted to BCR-
ABL1-like subtype
We identified 14 ABL/JAK class tyrosine kinase 
activating fusion genes among 77 BCR-ABL1-like 
cases (18%), and none among 76 non-BCR-ABL1-
like B-other cases (Table 1; Supplementary Table 1; 
Supplementary Figure 1). We found nine tyrosine kinase 
fusions predictive for activated ABL signaling: 4 EBF1-
PDGFRB, 2 SSBP1-CSF1R, and one each of ZMIZ1-
ABL1, FOXP1-ABL1, RCSD1-ABL2. Five tyrosine 
kinase fusions are predictive for activated JAK signaling: 
3 PAX5-JAK2, one each of BCR-JAK2 and TERF2-
JAK2. The exons included in the fusion transcripts were 
the same as described previously [6, 12–13], except for 
RCSD1 exon 3-ABL2 exon 5 (Supplementary Figure 
2), and TERF2 exon 10-JAK2 exon 19 with a deletion 
of the last 11 coding nucleotides of TERF2 exon 10 
(Supplementary Figure 3). All detected fusion transcripts 
encode in-frame fusion proteins as evaluated using 
ProteinPaint [14].
Table 2 summarizes the genomic analyses of the 
tyrosine kinase fusion cases. All PDGFRB, CSF1R 
and ABL1 fusions showed aberrant FISH patterns 
with the appropriate break apart FISH probes (Table 2, 
Supplementary Figure 4). In addition, both ABL1 fusions 
showed add(9)(q34) in their karyotypes (ABL1 is located 
on 9q34), together with add(10)(q21) in the ZMIZ1-ABL1 
case (ZMIZ1 is located on 10q22), and with del(3)(p13) 
in the FOXP1-ABL1 case (FOXP1 is located on 3p13). 
Two EBF1-PDGFRB cases showed an interstitial 5q 
deletion on array-CGH, one case arose by balanced t(5;5) 
translocation, and one case showed a more complex copy 
number alteration, with loss of EBF1 exon 16 and gain of 
a genomic region encompassing EBF1 exons 7-9 (Table 
2; Supplementary Figure 5A-B). EBF1 exon 16 deletion 
was confirmed by MLPA in the two interstitial 5q deletion 
cases and the complex case (Table 2). Genomic breaks 
were also detected in SSBP2-CSF1R, BCR2-JAK2 and 
TERF2-JAK2 fusions (Table 2, Supplementary Figure 
5C-F). Interestingly, one SSBP2-CSF1R fusion probably 
arose by chromothripsis of chromosome 5 (Supplementary 
Figure 5D). Finally, when we ordered the gene expression 
levels of the involved tyrosine kinases for the 153 B-other 
BCP-ALL cases, the expression in the fusion cases ranked 
in the top (median percentile 2.6%, range 0.7-14%; Table 
2).
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CRLF2 high expression and PAR1 deletions are 
common in both BCR-ABL1-like and B-other 
cases
High gene expression levels of the cytokine receptor 
CRLF2 were found in 16% of BCR-ABL1-like cases, none 
of which overlapped with ABL/JAK class tyrosine kinase 
fusion cases, and also in 16% of non-BCR-ABL1-like 
B-other cases. About 50% of CRLF2-high cases carried 
a JAK2 mutation [15]. The frequency of CRFL2 high 
expression cases with a PAR1 deletion, JAK2 mutation 
or both was similarly high in BCR-ABL1-like (9/12 
cases) and B-other cases (11/12 cases (Figure 1). CRLF2 
expression had no prognostic value in this Dutch/German 
BCP-ALL cohort as described previously [5].
Tyrosine kinase fusion cases are enriched for 
IKZF1 deletion variants
Next, we compared the frequency of B-cell 
development gene lesions between the tyrosine kinase 
fusion-positive BCR-ABL1-like cases, the fusion-
negative BCR-ABL1-like cases, and the non-BCR-
ABL1-like B-other cases. While IKZF1 deletions were 
common both in fusion-positive and fusion-negative 
BCR-ABL1-like cases (64% vs. 40%; p=0.14), IKZF1 
deletions other than exon 4-7 or full deletion, including 
deletion of exons 1, 1-2, 1-3, 2-3, 2-7, 2-8, 4-8, 5 and 
7-8, occurred more frequently in the fusion-positive 
compared with the fusion-negative BCR-ABL1-like cases 
(43% vs. 15%; p=0.03; Table 3). Except for deletions in 
EBF1, enriched in EBF1-PDGFRB fusion cases due to 
interstitial 5q deletion, none of the other genes detected 
by P335 MLPA (PAX5, ETV6, RB1, BTG1, CDKN2A/B, 
PAR1) showed an aberrant deletion frequency in tyrosine 
kinase fusion cases compared with non-BCR-ABL1-like 
B-other cases (Table 2). In the fusion-positive cases, 
CDKN2A/B deletion was less frequent than in the fusion-
negative BCR-ABL1-like cases (14% vs. 63%, p=0.002; 
Table 3 ). Two large genomic lesions previously described 
to occur in BCR-ABL1-like BCP-ALL, dic(9;20) and 
intrachromosomal amplification of chromosome 21 [3, 
16], were mutually exclusive with the identified tyrosine 
kinase fusions (Table 3).
Tyrosine kinase fusion cases show poor 
treatment response to induction therapy and 
high minimal residual disease levels
Finally, we evaluated clinical response 
characteristics. Of 12 tyrosine kinase fusion-positive cases 
with evaluable data, 5 patients did not achieve complete 
morphological remission at the end induction therapy; 4 of 
them were late responders, and one was a non-responder 
resulting in early death (Figure 2A). This non/late 
response rate at the end of induction therapy was higher in 
the fusion-positive cases compared with non-BCR-ABL1-
like B-other (42% vs. 7%, p=0.004) and also higher, albeit 
not statistically significant, compared with fusion-negative 
BCR-ABL1-like cases (42% vs. 17%, p=0.11; Table 3). 
Furthermore, fusion-positive cases were characterized 
by higher levels of minimal residual disease (MRD) 
compared with non-BCR-ABL1-like B-other cases at end 
of induction therapy (p=0.001) and before consolidation 
(p=0.002) and also, although less significant, compared 
with fusion-negative BCR-ABL1-like cases (p=0.09, 
p=0.04, respectively; Table 3). The 8-year cumulative 
incidence of relapse (CIR) in the BCR-ABL1-like group 
with tyrosine kinase fusions (35% ± 16%) was comparable 
with the remaining BCR-ABL1-like group (35% ± 6%), 
and worse than the non-BCR-ABL1-like B-other group 
(17% ± 5%; Gray p-value 0.066; Figure 2B). Of the three 
relapsed fusion-positive cases, one died of relapse and two 
were alive at end of follow-up (6-12 months). Remarkably, 
the percentage of males was higher in fusion-positive than 
fusion-negative BCR-ABL1-like cases (79% vs. 44%, 
p=0.04; Table 3).
Table 1: Frequency of identified tyrosine kinase fusion 
genes
Marker BCR-ABL1-
like (n=77)
Remaining 
B-other (n=76)
ABL1/ABL2 fusion 3.9% 0%
ZMIZ1-ABL1 1
FOXP1-ABL1 1
RCSD1-ABL2 1
PDGFRB fusion 5.2% 0%
EBF1-PDGFRB 4
CSF1R fusion 2.6% 0%
SSBP2-CSF1R 2
JAK2 fusion 6.5% 0%
PAX5-JAK2 3
BCR-JAK2 1
TERF2-JAK2 1
CRLF2 high 
expression* 15.6% 15.8%
PAR1 deletion** 10.5% 10.7%
*Expression of Affymetrix U133 Plus 2.0 probe set 
208303_s_at above the 90th percentile of the total BCP-
ALL group, as described previously [5].
**Deletion of IL3RA and CSF2RA and retention of 
CRLF2 as determined by MLPA.
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Table 2: Molecular characteristics of the identified tyrosine kinase fusion genes
Case
Tyrosine 
kinase 
fusion
Simplified karyotype Array-CGHa
EBF1 
exon 
16b
FISHc Expr rankd
Exons 
fused Validation
R32 EBF1-PDGFRB ND
deletion chr5: 149,494,702-
158,058,047 0.64
PDGFRB 
split 1% e15-e11 RT-PCR
A288 EBF1-PDGFRB
46,XY,t(2;12)(q23~24; 
q12)[20]/46,XY[14] diploid ND
PDGFRB 
split 5% e14-e11 RT-PCR
A472 EBF1-PDGFRB 46,XY[20]
deletion chr5: 149,494,702-
158,030,723;
gain chr5: 158,049,831-
158,428,865
0.62 PDGFRB split 4% e15-e11 RT-PCR
A428 EBF1-PDGFRB
46,XY[20].ish 
7(cep7,D7S522)x1,i(7)
(q10)(D7S522+, 
cep7+, D7S522+)
[13/25]
gain chr5: 158,222,469-
158,428,865 0.54
PDGFRB 
split 6% e15-e11 RT-PCR
A123 SSBP2-CSF1R ND
small deletions typical of 
chromothripsis 1.0
PDGFRB 
split 1% e16-e12 RT-PCR
A526 SSBP2-CSF1R 46,XY[10]
gain chr5: 80,740,416-
149,403,322 1.1
PDGFRB 
split 3% e16-e12 RT-PCR
A91 ZMIZ1-ABL1
47,XY,add(9)(q34), 
add(10)(q21),mar[9] diploid 1.1
ABL1 
split 2% e18-e2 RT-PCR
A26 FOXP1-ABL1
46,XY,del(3)(p13), 
add(9)(q34),i(22)
(q10), inc[6]
diploid 1.0 ABL1 split 14% e27-e4 TLA; PCR
A530 RCSD1-ABL2
46,XY[4]/42~ 
46,XY,inc[3] ND 0.71 ND 1% e3-e5
RT-PCR; 
TLA
A31 PAX5-JAK2
46,XX,del(1)
(q3?2q4?4), 
inc[2]/46,XX[18]
diploid 0.94 ND 1% e5-e19 RT-PCR
A286 PAX5-JAK2 46,XX[17] diploid 0.81 ND 6% e5-e19 RT-PCR
A204 PAX5-JAK2 ND diploid 0.96 ND 3% e5-e19 RT-PCR
A214 TERF2-JAK2 46,XY[20]
gain chr16: 67,958,182-
88,690,630;
deletion chr9: 593,494-
5,068,342
0.95 ND 3% e10-e19 RT-PCR; TLA
A216 BCR- JAK2 ND
deletion chr9: 194,193-
5,068,342; gain chr9: 
5,080,443-5,647,733;
gain chr22: 14,513,474-
21,885,107; deletion chr22: 
21,898,315-22,667,667
0.91 ND 1% e1-e17 RT-PCR; TLA
aGenome positions in build hg18, copy number changes shown for the genes involved in the fusion; see also Supplementary 
Figure 5.
bEBF1 exon 16 copy number ratio determined by MLPA. A value below 0.75 is called as a deletion.
cFISH break apart probes from Cytocell were used. The centromeric PDGFRB probe overlaps with CSF1R and can be used 
to detect breakpoints in CSF1R as well as in PDGFRB.
dExpr rank indicates the percentile in rank of the tyrosine kinase gene expression among 153 B-other BCP-ALL cases on 
Affymetrix U133 Plus 2 arrays.
ND, not determined.
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DISCUSSION
We identified ABL/JAK class tyrosine kinase 
fusion genes in 14/153 (9%) of DCOG/COALL B-other 
cases and these fusions were restricted to the BCR-
ABL1-like B-other subgroup. Given that these 153 cases 
were derived from a population-based selection of BCP-
ALL [5] and that these fusions do not co-occur with 
other driver leukemic fusions (BCR-ABL1, rearranged 
MLL, TCF3-PBX1, ETV6-RUNX1), ABL/JAK class 
tyrosine kinase fusions cases are estimated to represent 
approximately 2.5% of pediatric BCP-ALL, making this 
heterogeneous subgroup similar in size to the BCR-ABL1-
positive cytogenetic subtype. Although the number of 
cases evaluated in our study is modest, the frequency of 
tyrosine kinase fusion cases is similar to those reported in 
other cohorts: 3% ABL/JAK class fusions in a high-risk 
pediatric US cohort [6] and 5% ABL/JAK class fusions 
among Japanese pediatric B-other cases [9].
The most comprehensive detection of novel tyrosine 
kinase fusion genes requires transcriptome or whole 
genome sequencing. These costly methods have not 
been applied to complete cohorts but rather to subsets of 
cases, for example cases selected based on Philadelphia-
like gene expression or absence of sentinel chromosomal 
abnormalities, mostly in retrospective studies [6, 9]. More 
targeted approaches to detect recently identified tyrosine 
kinase fusions include RT-PCR [9], capture-targeted 
sequencing [17] or targeted locus amplification (TLA) 
and sequencing [18]. We combined genomic information 
from copy number, gene expression, targeted RT-PCR, 
FISH, and TLA to detect tyrosine kinase fusion genes in 
a representative cohort of 153 BCP-ALL cases without 
sentinel chromosomal aberrations that were taken from a 
population-based cohort of 574 cases at initial diagnosis of 
BCP-ALL. We found tyrosine kinase fusions exclusively 
in the BCR-ABL1-like B-other group, and found them 
non-overlapping with two chromosomal abnormalities 
Figure 1: Distribution of tyrosine kinase fusions and CRLF2 high expression cases. Pie diagrams showing the percentages of 
tyrosine kinase (TK) fusion cases and CRLF2 high expression among A. 77 BCR-ABL1-like B-other cases, and B. 76 non-BCR-ABL1-like 
B-other cases. Within the CRLF2 high expression cases, a sub-distribution of cases with JAK2 mutation and/or PAR1 deletion is shown. In 
the non-BCR-ABL1-like B-other cases, 2 PAR1-deleted cases were not tested for JAK2 mutations.
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Table 3: Clinical and molecular features of ABL/JAK class tyrosine kinase fusions
TK fusion-
positive
BCR-ABL1-
like
TK fusion-
negative
BCR-ABL1-
like
Fisher P
TK fusion-positive 
vs. TK fusion-
negative BCR-ABL1-
like
non-BCR-
ABL1-like 
B-other
Fisher P
TK fusion-positive 
vs. non-BCR-
ABL1-like B-other
Clinical features
male 11/14 (79%) 28/63 (44%) 0.036 44/76 (58%) 0.23
age ≥ 10 years 7/14 (50%) 18/63 (29%) 0.2 25/76 (33%) 0.24
WBC ≥ 50x109/L 6/14 (43%) 32/63 (51%) 0.77 23/76 (30%) 0.37
NCI high riska 11/14 (79%) 43/63 (68%) 0.53 42/76 (55%) 0.14
MRD TP1b
high
intermediate
low
7/11 (64%)
3/11 (27%)
1/11 (9%)
17/36 (47%)
4/36 (11%)
15/36 (42%)
0.093
10/45 (22%)
5/45 (11%)
30/45 (67%)
0.001
MRD TP2b
high
intermediate
low
4/7 (57%)
0/7 (0%)
3/7 (43%)
4/30 (13%)
3/30 (10%)
23/30 (77%)
0.037
1/34 (3%)
1/34 (3%)
32/34 (94%)
0.002
Risk arm MR or HR 12/14 (86%) 52/62 (84%) 1 47/74 (64%) 0.13
Prednisone poor responsec 2/7 (29%) 3/31 (10%) 0.22 3/31 (10%) 0.22
No CR after inductiond 5/12 (42%) 10/58 (17%) 0.11 5/73 (7%) 0.004
Molecular features
IKZF1 deletion Total 9/14 (64%) 25/62 (40%) 0.14 13/73 (18%) 0.0009
     Commone 3/14 (21%) 16/62 (26%) 1 5/73 (7%) 0.11
      Otherf 6/14 (43%) 9/62 (15%) 0.026 8/73 (11%) 0.009
EBF1 deletion 4/14 (29%) 9/62 (15%) 0.24 3/73 (4%) 0.012
EBF1 single exon 16 del 4/14 (29%) 0/62 (0%) 0.0008 0/73 (0%) 0.0005
PAX5 deletion/amp 3/14 (21%) 32/62 (52%) 0.072 26/73 (36%) 0.37
ETV6 deletion 2/14 (14%) 9/62 (15%) 1 18/75 (24%) 0.73
BTG1 deletion 2/14 (14%) 1/62 (2%) 0.085 6/74 (8%) 0.61
CDKN2A/B deletion 2/14 (14%) 39/62 (63%) 0.002 29/75 (39%) 0.13
RB1 deletion 1/14 (7%) 6/62 (10%) 1 5/74 (7%) 1
CRLF2 high expression 0/14 (0%) 12/63 (19%) 0.11 12/76 (16%) 0.2
PAR1 deletion 0/14 (0%) 8/62 (13%) 0.34 8/75 (11%) 0.35
dic(9;20) 0/14 (0%) 15/57 (26%) 0.031 2/74 (3%) 1
iAMP21 0/14 (0%) 10/57 (18%) 0.19 2/74 (3%) 1
aNCI-Rome high risk is defined by white blood cell count (WBC) ≥_50x109/L and/or age ≥ 10 years.
bMinimal residual disease PCR high (≥10-3), intermediate (≥10-4 and <10-3), low (<10-4); TP1, after the first induction course of 
chemotherapy, DCOG ALL-10 protocol day 33, ALL-9 protocol day 42, COALL day 28; TP2, before consolidation, day 79.
cPrednisone response on day 8 ≥1.0x109 blasts/L (DCOG ALL-8/10 protocols).
dComplete remission (CR) after induction (day 33 in DCOG ALL-9/10, day 42 in ALL-8) is defined on morphological 
grounds by the presence of <5% leukemic blasts and regenerating hematopoiesis.
eCommon IKZF1 deletions are defined as full deletion (exons 1-8) and deletion of exons 4-7.
fOther IKZF1 deletions included deletion of exons 1, 1-2, 1-3, 2-3, 2-7, 2-8, 4-8, 5 and 7-8.
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that were described earlier to occur in BCR-ABL1-like 
cases, iAMP21 and dic(9;20) [3]. Moreover, while CRLF2 
high expression cases are present both in BCR-ABL1-like 
and non-BCR-ABL1-like B-others, we found that tyrosine 
kinase fusions and high CRLF2 expression were mutually 
exclusive. The current study did not aim at discovering 
novel TK fusions, therefore there is a small probability 
that a sample with a novel tyrosine kinase gene is included 
in the tyrosine kinase fusion negative group.
Our finding that tyrosine kinase fusions are only 
found in patients with BCR-ABL1-like features, and 
our earlier finding that tyrosine kinase fusion cases are 
identified by both the St. Jude and Erasmus MC BCR-
ABL1-like expression signatures [16], means that a pre-
screening method based on gene expression, such as the 
US-developed low density array, is suitable to narrow 
down the patient population to be screened for tyrosine 
kinase fusions. An alternative approach screens patients 
selected by poor early clinical response for tyrosine kinase 
fusions [10].
We found that ABL/JAK kinase fusion cases 
were characterized by poor initial response to induction 
treatment, high MRD levels, and a higher relapse rate 
compared with non-BCR-ABL1-like B-other ALL cases 
but a comparable relapse rate as BCR-ABL1-like ALL 
without tyrosine kinase fusions. In correspondence, a 
recent Japanese study showed that the event-free survival 
of tyrosine kinase-activating fusion cases (albeit including 
CRLF2 rearrangements) was unfavorable compared with 
fusion-negative BCP-ALL [9], Schwab et al. described 
that EBF1-PDGFRB-positive patients were MRD positive 
at the end of induction [10], and Roberts et al. described 
MRD positivity and inferior survival in the total group 
of Philadelphia-like cases [6]. Recent protocols using 
MRD-based risk-directed therapy suggest that initial 
poor treatment response in tyrosine kinase fusion-positive 
cases or the total group of Philadelphia-like cases can be 
overcome with intensive chemotherapy, leading to durable 
remission [10, 19]. Ex vivo leukemic patients’ cells with 
JAK and ABL class fusions were shown to be sensitive 
to tyrosine kinase inhibitors [6–7, 15]. Promising early 
clinical results suggests that ABL class tyrosine kinase 
fusion patients respond well to ABL class inhibitors 
imatinib or dasatinib [6, 10, 20–21]. Together with our 
data, these reports stress the importance of prospective 
detection of tyrosine kinase fusions and incorporation of 
tyrosine kinase inhibitors in ALL treatment protocols to 
improve outcome.
Figure 2: BCR-ABL1-like tyrosine kinase fusion cases. A. Clinical characteristics and follow-up for the tyrosine kinase fusion 
cases. Barplot representing years from diagnosis to event or censoring. Treatment protocol and arm, prednison window response (Pred), 
morphological response after induction therapy (Resp), minimal residual disease (MRD), and deletion status of IKZF1 are shown. MRD 
monitoring by PCR was performed for research purposes in ALL-9 and COALL03 and for MRD-guided risk stratification in ALL-10. WT 
indicates no IKZF1 deletion. For definition of Pred, Resp, and MRD see footnotes Table 3. Response ‘unkn’ indicates patients with low 
cellularity bone marrow which could not be evaluated. * Indicates patients who received bone marrow transplant, for which HR-treated 
cases were eligible. B. Cumulative incidence of relapse and non-response curves for tyrosine kinase fusion positive BCR-ABL1-like cases, 
fusion-negative BCR-ABL1-like cases, and non-BCR-ABL1-like B-other cases. Relapse and non-response were considered as events, death 
as competing event. Cumulative incidence probabilities were estimated using a competing risk model, equality was tested with the Gray 
test.
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MATERIALS AND METHODS
Patient samples
This study comprised 574 children with newly 
diagnosed BCP-ALL enrolled in consecutive Dutch 
Childhood Oncology Group trials (DCOG ALL-8, ALL-9 
and ALL-10) [5, 22] and German Cooperative ALL trials 
(COALL 06-97 and 07-03) [23–24]. These patient cohorts 
were described and analyzed together previously [3, 5]. 
Written informed consent was obtained from parents 
or guardians and institutional review boards approved 
the use of excess of diagnostic material for research 
purposes. These studies were conducted in accordance 
with the Declaration of Helsinki. Mononuclear cells 
were collected using Lymphoprep sucrose gradient 
centrifugation (Nycomed Pharma, Oslo, Norway) from 
bone marrow aspirates and peripheral blood samples 
obtained prior to treatment. Where needed, mononuclear 
cells were enriched to >90% leukemic cells by depleting 
normal cells using anti-CD marker coated magnetic beads 
(Dynal, Oslo, Norway) as described previously [25]. DNA 
and total RNA were isolated using TRIzol (Invitrogen Life 
Technologies, Breda, the Netherlands) and quantified using 
a Nanodrop ND1000 (Nanodrop, Wilmington, DE). From 
this cohort, we focused on B-other patients, defined as 
patients without the sentinel chromosomal abnormalities 
BCR-ABL1, MLL rearrangements, ETV6-RUNX1, TCF3-
PBX1, and high hyperdiploidy. Among the B-other cases, 
BCR-ABL1-like cases identified by hierarchical clustering 
of gene expression data were described previously in our 
cohort [5]. For 153 out of 204 B-other/BCR-ABL1-like 
cases in the cohort, tyrosine kinase fusion testing was 
performed (see flow chart in Supplementary Figure 1).
Tyrosine kinase fusion detection
Detection of tyrosine kinase fusion genes was 
performed by RT-PCR followed by Sanger sequencing 
for seven fusion transcripts EBF1-PDGFRB, PAX5-
JAK2, NUP214-ABL1, RANBP2-ABL1, ETV6-ABL1, 
RCSD1-ABL1 and STRN3-JAK2 described by Roberts et 
al. [7]. In addition, we performed a more extensive RT-
PCR panel [6] enabling detection of 30-39 fusion genes 
(depending on availability of material). For RT-PCR 
primers see Supplementary Table 2. We used targeted 
locus amplification for 21 cases to detect fusion genes 
involving ABL1, PDGFRB, CSF1R, ABL2, TYK2, and 
JAK2 (TLA, Cergentis, Utrecht, the Netherlands) [18, 
26]. We used break apart FISH with PDGFRB/CSF1R 
and ABL1 probes (Cytocell) to confirm fusions. The 
methods applied to each case depended on the type and 
amount of available patient material and are indicated in 
Supplementary Table 3 and summarized in Supplementary 
Figure 1. For the comparison of tyrosine kinase fusion 
positive versus negative patients, we included 153 samples 
that were tested at least by the 7-fusion RT-PCR panel. 
For expression rank analysis (Table 2), the Affymetrix 
microarray gene expression values for each tyrosine kinase 
gene were ranked from high to low for the 153 samples. 
Then the percentile rank of the fusion-positive case among 
the 153 samples was calculated.
Genome-wide DNA copy number arrays (array-
CGH)
Copy number analysis was performed using Agilent 
SurePrint G3 Hmn 4x180K arrays (Agilent Technologies, 
Amstelveen, the Netherlands) co-hybridized with 1 µg 
patient DNA labeled with ULS-Cy5 and 1 µg reference 
genomic DNA male pool (G147A, Promega, Leiden, the 
Netherlands) labeled with ULS-Cy3 (Agilent Genomic 
DNA ULS Labeling Kit). Copy number microarray data 
were normalized using median log ratio in the CGHcall 
[27] version 2.14.0, centralized using CGHnormaliter [28] 
version 1.8.0, and segmented and called using CGHcall 
default settings (-1 for loss, 0 for diploid, 1 for gain and 2 
for amplification) in R version 2.14.1.
Multiplex ligation-dependent probe amplification
The SALSA P335 ALL-IKZF1 (a3) and the SALSA 
P202 Multiplex Ligation-dependent Probe Amplification 
(MLPA) assays (MRC-Holland) were used to identify or 
confirm genomic lesions on the following genes: IKZF1, 
CDKN2A, CDKN2B, ETV6, PAX5, RB1, BTG1 and 
EBF1 as described previously [5, 29]. In short, 125 ng 
of genomic DNA was used to generate DNA fragments 
with incorporated FAM nucleotides according to the 
manufacturer’s protocol. The amplified fragments were 
quantified using an ABI-3130 genetic analyzer (Applied 
Biosystems, Carlsbad, CA). Peak intensities were 
normalized to the manufacturer’s control probes and to 
a synthetic control reference generated from five normal 
DNA samples in the same MLPA run. A peak ratio lower 
than 0.75 was considered a deletion, a ratio between 0.75 
and 1.3 was considered normal copy number, a ratio 
higher than 1.3 was considered a gain in copy number.
Targeted locus amplification
Targeted Locus Amplification (TLA) combined 
with deep-sequencing was used to detect fusion genes and 
sequence mutations in regions up to 100 kb around a pre-
selected primer pair by crosslinking of physically proximal 
genomic sequences as described before [26]. Briefly, DNA 
and protein in 10-15 million viable leukemic blast cells 
were crosslinked in a 2% formaldehyde solution. Cells 
were lysed and DNA was digested with NlaIII, followed 
by ligation, de-crosslinking and DNA purification. 
DNA molecules were trimmed with NspI and ligated 
at a concentration of 5 ng/μl to promote intramolecular 
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ligation to DNA fragments of approximately 2 kb. These 
chimeric fragments were PCR amplified, sonicated 
and adaptor-ligated for paired-end high-throughput 
Illumina sequencing. A total of 31 primer sets targeting 
19 recurrently affected genes were designed and 
multiplexed, including the genes involved in the classical 
cytogenetic subtypes MLL, RUNX1, TCF3, and IKZF1, 
the tyrosine kinase genes ABL1, ABL2, PDGFRB, CSF1R, 
JAK1, JAK2, JAK3, FLT3, and TYK2, and the cytokine 
signaling genes CRLF2, EPOR, IL7R, TSLP, SH2B3, and 
IL2RB [17].
Fluorescent in-situ hybridization (FISH)
FISH was performed on interface nuclei using break 
apart probes (Cytocell, Cambridge, UK) for PDGFRB and 
ABL1. The FISH probes for PDGFRB overlap with the 
neighboring CSF1R locus. At least 100 interphase nuclei 
were evaluated.
Reverse transcriptase PCR (RT-PCR)
cDNA was synthesized from 1 µg total or copy 
RNA using M-MLV reverse transcriptase and combined 
oligo-dT and pdN6 priming in 20 µl (Promega, Madison, 
WI). PCR was performed on 2.5 µl cDNA using Taq 
polymerase, MgCl2 and buffer from Applied Biosystems 
(Bleiswijk, Netherlands). For primer sequences see 
Supplementary Table 2, for RT-PCR results per sample 
see Supplementary Table 3.
Association with clinical outcome
Cumulative incidence of relapse (CIR) was 
estimated using a competing risks model. We considered 
relapse as event, and death as competing event. To test 
for equality of CIRs, Gray’s test has been applied. The 
CIR probability (pCIR) with standard error was reported. 
Outcome analyses were performed in R 3.0.1, using the 
packages cmprsk version 2.2-6 [30], mstate version 0.2.6 
[31], and survival version 2.37-4 [32].
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